<DOC>
	<DOCNO>NCT00381615</DOCNO>
	<brief_summary>This study aim explore safety immunogenicity two formulation Meningococcal B Vaccine administer healthy infant .</brief_summary>
	<brief_title>Prevention , Randomized , Open Label , Active Control , Parallel Assignment , Safety/Efficacy Study</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects eligible enrol study : 1. healthy 2month old infant ( 5589 day , inclusive ) , bear full term pregnancy estimate gestational age ≥37 week birth weight ≥2.5 kg ; 2. parent/legal guardian provide write informed consent nature study explain ; 3. available visit schedule study ; 4. good health determine : 1. medical history 2. physical examination 3. clinical judgment investigator Individuals enrol study : 1. whose parents/legal guardian unwilling unable give write informed consent participate study ; 2. previously receive meningococcal B vaccine ; 3. receive prior vaccination Diphtheria Tetanus Pertussis ( DTP ) ( acellular whole cell ) , Inactivated Polio Vaccine ( IPV ) Oral Polio Vaccine ( OPV ) , H influenzae type b ( Hib ) Heptavalent Pneumococcal Conjugate ( PC7 ) vaccine ; 4. previous ascertain suspected disease cause N meningitidis , S pneumoniae , C diphtheriae , tetani , Poliovirus , Hib , B pertussis ( history laboratory confirm , clinical condition spasmodic cough period ≥2weeks associate apnea whoop ) ; 5. household contact and/or intimate exposure individual laboratory confirm N meningitidis , B pertussis , Hib , C diphtheriae Polio infection since birth ; 6. history anaphylactic shock , asthma , urticaria allergic reaction previous vaccination know hypersensitivity vaccine component ; 7. experience significant acute chronic infection within previous 7 day experience fever ( ≥38.0°C ) within previous 3 day ; 8. present suspect serious acute chronic disease ( e.g. , sign cardiac , renal failure , hepatic disease , severe malnutrition insulin dependent diabetes ) , progressive neurological disease , genetic anomaly/known cytogenic disorder ( e.g. , Down 's syndrome ) ; 9. leukemia , lymphoma ; 10. know suspect autoimmune disease impairment/alteration immune function result ( example ) : 1. receipt immunosuppressive therapy since birth 2. receipt immunostimulants since birth 3. receipt systemic corticosteroid since birth 11. suspect know HIV infection HIV related disease ; 12. ever receive blood , blood product and/or plasma derivative parenteral immunoglobulin preparation birth full length study ; 13. know bleeding diathesis , condition might associate prolonged bleeding time ; 14. experienced seizure , either associate fever part underlie neurological disorder syndrome 15. take antibiotic within 7 day prior enrollment ( exception : antibiotic take daily within 14 day last dose ) ; 16. either receive , intent immunize vaccine ( ) , respect study vaccine , within 30 day prior throughout study period ; 17. ever receive another investigational agent birth prior enrollment unwilling refuse participation another investigational trial end study ; 18. whose parents/legal guardian , plan leave area study site end study period ; 19. condition , opinion investigator , might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>55 Days</minimum_age>
	<maximum_age>89 Days</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Meningococcal disease</keyword>
	<keyword>prevention</keyword>
	<keyword>vaccination</keyword>
</DOC>